Central Nervous System News and Research

RSS

Marinus initiates ganaxolone Phase 2 trial in posttraumatic stress disorder

Marinus Pharmaceuticals, Inc., the leader in the development of neurosteroids for central nervous system disorders, today announced commencement of a proof-of-concept clinical trial of its lead candidate ganaxolone for the treatment of posttraumatic stress disorder.

22 Apr 2011

Neuralstem signs MoU with BaYi Brain Hospital for ischemic stroke program in China

Neuralstem, Inc. (NYSE Amex: CUR) announced it has signed a Memorandum of Understanding with BaYi Brain Hospital in Beijing, China.

21 Apr 2011

Adeona, TG United enter commercial-scale manufacturing agreement for reaZin

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it has executed an agreement with TG United, Inc. of Brooksville, Florida, to provide commercial-scale manufacturing capabilities for reaZin. Adeona is developing reaZin, its product candidate for the dietary management of Alzheimer's disease and mild cognitive impairment, as a prescription medical food.

20 Apr 2011

Combination therapy restores skilled use of limb in rodent model

After the acute treatment window closes, the only effective treatment for stroke is physical/occupational therapy. Now scientists from Children's Hospital Boston report a two-pronged molecular therapy that leads to significant recovery of skilled motor function in a rat model of stroke.

20 Apr 2011

Teva presents new CNS products study data in RRMS, Parkinson's at AAN meeting

Teva Pharmaceutical Industries Ltd. today announced that several new studies further support the efficacy and safety of the company's innovative central nervous system products.

12 Apr 2011

Insight into neurodegenerative diseases

For years, researchers in genome stability have observed that several neurodegenerative diseases-including Huntington's disease-are associated with cell-killing proteins that are created during expansion of a CAG/CTG trinucleotide repeat.

12 Apr 2011

Positive results from laquinimod Phase III ALLEGRO study in multiple sclerosis to be presented at AAN

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today results from the two-year Phase III ALLEGRO study of laquinimod, an oral, once-daily, investigational immunomodulator for the treatment of relapsing forms of multiple sclerosis (MS). These data will be presented as late-breaking research at the Annual Meeting of the American Academy of Neurology (AAN).

12 Apr 2011

Epilepsy medication USL255 associated with less fluctuation in plasma levels compared to topiramate IR

Upsher-Smith Laboratories today announced the presentation of data indicating that once daily administration of USL255, a proprietary extended-release (ER) formulation of the epilepsy medication topiramate, was associated with less fluctuation in topiramate plasma levels compared to immediate-release (IR) topiramate administered twice daily in healthy volunteers.

12 Apr 2011

Positive top-line results from Biogen BG-12 Phase 3 trial in RRMS

Biogen Idec announced today positive top-line results from DEFINE, the first of two pivotal Phase 3 clinical trials designed to evaluate the investigational oral compound BG-12 as a monotherapy in people with relapsing-remitting multiple sclerosis.

11 Apr 2011

Takeda, Heptares collaborate to develop new drugs against CNS disorders

Heptares Therapeutics and Takeda Pharmaceutical Company today announced the formation of a two-year drug discovery collaboration focused on a single G-protein coupled receptor that plays an important role in the pathology of central nervous system disorders.

11 Apr 2011

Gilenya can reduce risk of disability progression in patients with RRMS

A new analysis demonstrated that Gilenya reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis, regardless of treatment history. This analysis of the phase III two-year FREEDOMS study is one of 11 abstracts on Gilenya being presented at the 63rd annual meeting of the American Academy of Neurology.

11 Apr 2011

FDA accepts Antares Pharma's Anturol NDA for filing, assigns PDUFA date

Antares Pharma, Inc. today announced the New Drug Application (NDA) for Anturol® Gel in patients with overactive bladder (OAB) was accepted for filing for review by the U.S. Food and Drug Administration (FDA). Anturol is an oxybutynin gel incorporating Antares' ATD Gel technology.

8 Apr 2011

ASBMB honors Stanford professor with DeLano Award for Computational Biosciences

Stanford University professor Axel T. Brunger has been named the winner of the American Society for Biochemistry and Molecular Biology's inaugural DeLano Award for Computational Biosciences. Brunger will present his award lecture, titled "Towards Structural Biology with Single Molecules" at 9:03 a.m. on Wednesday, April 13, at the Experimental Biology 2011 conference at the Walter E. Washington Convention Center in Washington, D.C.

8 Apr 2011

Adult survivors of childhood CNS tumors have persistent, unmet health care needs

Patients treated in childhood for tumours of the central nervous system have persistent and unmet health care needs even in adulthood, according to a comprehensive study from Karolinska Institutet which investigated an entire cohort of patients in Sweden.

8 Apr 2011

A2AAR-selective agonists may prevent permanent vision damage from traumatic optic nerve injury

Scientists want to protect the optic nerve when the eye takes a blow on the battlefield or in a car wreck.

7 Apr 2011

FDA approves Horizant Extended-Release Tablets for Restless Legs Syndrome

GlaxoSmithKline and XenoPort, Inc. announced Wednesday that the U.S. Food and Drug Administration (FDA) has approved Horizant™ (gabapentin enacarbil) Extended-Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome in adults. Horizant is not recommended for patients who are required to sleep during the daytime and remain awake at night.

7 Apr 2011

TZDs might serve as new agents for addiction treatment

Thiazolidinediones are a class of medications that are commonly prescribed to treat type-2 diabetes, while fibrates are a structurally-related class of medications that are prescribed to modulate lipid levels in both diabetic and non-diabetic patients to help reduce the risk of cardiovascular disease.

6 Apr 2011

Retrovirus XMRV may not be associated with Chronic Fatigue Syndrome in the central nervous system

There has been substantial mystery surrounding the origins of Chronic Fatigue Syndrome (CFS), a condition affecting as many as four million Americans and marked by symptoms that include a sense of weariness that sleep does not improve and difficulty with memory and concentration.

6 Apr 2011

Scientists discover new compounds that may help fight against parasitic diseases

Trypanosomatid parasites cause diseases like African sleeping sickness, Chagas' disease and leishmaniasis. Leishmaniasis affects about 12 million people worldwide, mostly in developing countries. Current drug treatments are inadequate due to drug toxicity and resistance.

5 Apr 2011

SMT announces $10.5 million financing to develop novel device for use in TAVI procedures

SMT Research and Development Ltd. of Herzliya Pituach, Israel announced today a significant investment by OrbiMed Advisors LLC. SMT is finalizing the development of a novel embolic protection device designed for use during Transcatheter Aortic Valve Implantation procedures.

4 Apr 2011

Central Nervous System News and Research

Marinus initiates ganaxolone Phase 2 trial in posttraumatic stress disorder

Neuralstem signs MoU with BaYi Brain Hospital for ischemic stroke program in China

Adeona, TG United enter commercial-scale manufacturing agreement for reaZin

Combination therapy restores skilled use of limb in rodent model

Teva presents new CNS products study data in RRMS, Parkinson's at AAN meeting

Insight into neurodegenerative diseases

Positive results from laquinimod Phase III ALLEGRO study in multiple sclerosis to be presented at AAN

Epilepsy medication USL255 associated with less fluctuation in plasma levels compared to topiramate IR

Positive top-line results from Biogen BG-12 Phase 3 trial in RRMS

Takeda, Heptares collaborate to develop new drugs against CNS disorders

Gilenya can reduce risk of disability progression in patients with RRMS

FDA accepts Antares Pharma's Anturol NDA for filing, assigns PDUFA date

ASBMB honors Stanford professor with DeLano Award for Computational Biosciences

Adult survivors of childhood CNS tumors have persistent, unmet health care needs

A2AAR-selective agonists may prevent permanent vision damage from traumatic optic nerve injury

FDA approves Horizant Extended-Release Tablets for Restless Legs Syndrome

TZDs might serve as new agents for addiction treatment

Retrovirus XMRV may not be associated with Chronic Fatigue Syndrome in the central nervous system

Scientists discover new compounds that may help fight against parasitic diseases

SMT announces $10.5 million financing to develop novel device for use in TAVI procedures

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News